Q3 EPS Forecast for Liquidia Technologies Cut by Analyst

Key Points

• Investment analysts at HC Wainwright have downgraded their Q3 2025 earnings per share (EPS) forecast for Liquidia Technologies from ($0.33) to ($0.37), while maintaining a "Buy" rating with a $35.00 target price.
• The company reported a revenue increase of 141.5% year-over-year, achieving $8.84 million for the quarter, despite posting a loss of ($0.49) EPS which was below analysts' expectations.
• Analyst ratings are largely positive, with one sell rating, one hold, seven buy ratings, and two strong buy ratings, resulting in a consensus rating of "Moderate Buy" and an average price target of $31.40.

Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for shares of Liquidia Technologies in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.37) for the quarter, down from their previous estimate of ($0.33). HC Wainwright has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Liquidia Technologies' current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia Technologies' Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at $0.27 EPS, FY2027 earnings at $0.76 EPS, FY2028 earnings at $1.51 EPS and FY2029 earnings at $1.95 EPS.

Several other research firms have also recently weighed in on LQDA. BTIG Research restated a "buy" rating on shares of Liquidia Technologies in a research note on Tuesday, May 27th. Oppenheimer set a $13.00 target price on Liquidia Technologies and gave the stock an "underperform" rating in a research report on Monday, May 19th. Jefferies Financial Group started coverage on Liquidia Technologies in a report on Friday. They set a "buy" rating and a $43.00 price target for the company. Raymond James Financial increased their price target on Liquidia Technologies from $33.00 to $41.00 and gave the stock a "strong-buy" rating in a report on Wednesday, August 13th. Finally, Scotiabank raised their target price on Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $32.11.

Liquidia Technologies Price Performance

NASDAQ:LQDA traded down $0.61 during trading hours on Friday, reaching $27.11. 2,242,984 shares of the company were exchanged, compared to its average volume of 1,785,113. The company has a market capitalization of $2.33 billion, a P/E ratio of -15.95 and a beta of 0.14. Liquidia Technologies has a 1-year low of $8.75 and a 1-year high of $28.00. The company has a debt-to-equity ratio of 9.84, a current ratio of 2.49 and a quick ratio of 2.41. The business has a 50 day moving average of $16.50 and a 200 day moving average of $15.63.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.06). The firm had revenue of $8.84 million for the quarter, compared to analyst estimates of $3.90 million. Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.Liquidia Technologies's quarterly revenue was up 141.5% on a year-over-year basis.

Hedge Funds Weigh In On Liquidia Technologies

Several hedge funds have recently modified their holdings of LQDA. Geode Capital Management LLC lifted its position in shares of Liquidia Technologies by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock worth $15,753,000 after buying an additional 101,597 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Liquidia Technologies by 69.1% during the 4th quarter. Wells Fargo & Company MN now owns 30,020 shares of the company's stock worth $353,000 after buying an additional 12,267 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Liquidia Technologies during the 4th quarter worth approximately $952,000. Invesco Ltd. lifted its position in shares of Liquidia Technologies by 2,675.0% during the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after buying an additional 674,940 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Liquidia Technologies by 6.5% during the 4th quarter. Legal & General Group Plc now owns 83,286 shares of the company's stock worth $979,000 after buying an additional 5,048 shares in the last quarter. Institutional investors own 64.54% of the company's stock.

Insiders Place Their Bets

In related news, insider Scott Moomaw sold 4,797 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $68,501.16. Following the transaction, the insider owned 223,231 shares of the company's stock, valued at approximately $3,187,738.68. This trade represents a 2.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 30,000 shares of the firm's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $20.00, for a total transaction of $600,000.00. Following the completion of the transaction, the chief financial officer directly owned 376,412 shares in the company, valued at approximately $7,528,240. The trade was a 7.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,277 shares of company stock worth $1,469,392 in the last 90 days. Company insiders own 30.10% of the company's stock.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).